Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cellula

Affiliation auteurs!!!! Error affiliation !!!!
TitreSimilar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cellula
Type de publicationJournal Article
Year of Publication2018
AuteursDecroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux M-P, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis J-H, Charbonnier A, Dauriac C, Bay J-O, Blaise D, Deconinck E, Jubert C, Raus N, de Latour RPeffault, Dhedin N
JournalAMERICAN JOURNAL OF HEMATOLOGY
Volume93
Pagination416-423
Date PublishedMAR
Type of ArticleArticle
ISSN0361-8609
Résumé

{Patients with acute myeloid leukemia (AML) in relapse or refractory to induction therapy have a dismal prognosis. Allogeneic hematopoietic stem cell transplantation is the only curative option. In these patients, we aimed to compare the results of a myeloablative transplant versus a sequential approach consisting in a cytoreductive chemotherapy followed by a reduced intensity conditioning regimen and prophylactic donor lymphocytes infusions. We retrospectively analyzed 99 patients aged 18-50 years, transplanted for a refractory (52%) or a relapsed AML not in remission (48%). Fifty-eight patients received a sequential approach and 41 patients a myeloablative conditioning regimen. Only 6 patients received prophylactic donor lymphocytes infusions. With a median follow-up of 48 months, 2-year overall survival was 39%, 95% confidence interval (CI) (24-53) in the myeloablative group versus 33%, 95% CI (21-45) in the sequential groups (P=.39), and 2-year cumulative incidence of relapse (CIR) was 57% versus 50% respectively (P=.99). Nonrelapse mortality was not higher in the myeloablative group (17% versus 15%

DOI10.1002/ajh.25004